Every 10-Q that Fennec Pharmaceuticals Inc. (FENC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FENC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FENC filings page.
Fennec Pharmaceuticals reported strong growth and a shift to profitability driven by commercialization of PEDMARK®. For the quarter ended June 30, 2026, total revenue was $17.9 million, up from $9.7 million a year earlier, including PEDMARK net product sales of $17.2 million and $0.7 million of other revenue from its PEDMARQSI® license with Norgine.
Quarterly income from operations was $1.7 million versus a loss of $2.7 million, and net income was $2.0 million versus a net loss of $3.2 million. For the first six months of 2026, revenue reached $33.0 million, with net income of $2.2 million compared to a $4.3 million loss in 2025, and operating cash flow improved to $2.4 million.
Growth was accompanied by a sharp increase in selling and marketing expense to $10.7 million in the quarter, reflecting continued U.S. commercialization and support for international expansion through Norgine. Fennec ended June 30, 2026 with $41.2 million in cash and cash equivalents and $42.4 million of stockholders’ equity, and believes existing cash plus expected revenues will fund operations for at least the next twelve months.
Fennec Pharmaceuticals Inc. reported strong quarterly growth as PEDMARK product sales, net, rose to $15.1 million for the three months ended March 31, 2026, up from $8.8 million a year earlier. Higher revenue helped the company swing from a net loss of $1.2 million in 2025 to net income of $0.2 million and positive operating cash flow of $2.4 million. Cash and cash equivalents increased to $40.2 million, with working capital of $57.3 million, and management believes this is sufficient to fund operations for at least twelve months. Fennec also highlighted its ex‑U.S. PEDMARQSI® license with Norgine, which included an upfront payment of about $43 million and potential milestones up to roughly $230 million, and a settlement with Cipla that delays U.S. generic sodium thiosulfate entry until September 1, 2033 under agreed terms.
Fennec Pharmaceuticals (FENC) reported Q3 2025 results with PEDMARK net product sales of $12,462 (up from $6,974 a year ago). For the nine months, net product sales were $30,865 versus $21,655 in 2024. Q3 operating loss was $(189) and net loss was $(638), or $(0.02) per share.
Cash and cash equivalents were $21,947, total assets $49,261, and total liabilities $53,753, resulting in a stockholders’ deficit of $(4,492). The balance sheet reflects a term loan of $18,206 and accrued PIK interest of $1,271 under the Petrichor notes; following December 2024 redemptions, $19,477 remained outstanding as of September 30, 2025. Operating cash flow for the nine months was $(6,511); financing cash flow was $1,824.
The company continues to account for its 2024 Norgine license—approximately $43,000 was received upfront, with $24,561 recorded as long‑term contract liability. As of November 10, 2025, common shares outstanding were 28,116,829.